Crinetics Pharmaceuticals CRNX 深 沪
已收盘 10-17 16:00:00 美东时间
41.57
-0.740
-1.75%
华盛通- 最 高42.795
- 今 开42.08
- 成交量 150.92万股
- 最 低 41.07
- 昨 收 42.31
- 总市值 39.15亿
- 52周最高 62.53
- 市盈率 静 --
- 换手率 1.60%
- 52周最低 24.10
- 委 比 -83.22%
- 总股本 9417.60万
- 历史最高 62.53
- 量 比 1.18
- 振 幅 4.08%
- 历史最低 10.63
- 每 手 1
- 风险率 10.29%
个股概要
财务分析
公司资料
相关新闻
分红派息
- 分时图
- 日k
- 周k
- 月k
相关新闻
更多Crane NXT Announces Dates for Third Quarter 2025 Earnings Release and Earnings Call
Crane NXT, Co. announced its schedule for the third quarter 2025 results. The earnings release will be available on November 5, 2025, after market close via its website. An earnings call will follow on November 6, 2025, at 10:00 a.m. ET, with the webcast archived online.
10-08 20:05
美股大行评级 | 潜在涨幅超31%！摩根大通维持通用汽车"超配"评级，目标价从60美元升至80美元
今日重点评级关注：Maxim Group：上调Adial Pharmaceuticals评级至"买入"，目标价1.5美元；BTIG：维持Climb Bio"买入"评级，目标价从7美元升至8美元
10-01 20:13
美股大行评级 | 潜在涨幅207.38%！GoldMining获HC Wainwright升目标价至3.75美元，维持"买入"评级
今日重点评级关注：HC Wainwright & Co.：维持GoldMining"买入"评级，目标价从3.25美元升至3.75美元；摩根士丹利：维持Crinetics Pharmaceuticals"超配"评级，目标价从65美元升至77美元
09-30 14:16
Morgan Stanley Maintains Overweight on Crinetics Pharmaceuticals, Raises Price Target to $77
Morgan Stanley analyst Jeffrey Hung maintains Crinetics Pharmaceuticals (NASDAQ: CRNX) with a Overweight and raises the price target from $65 to $77.
09-30 01:05
美股大行评级 | 潜在涨幅485.44%！Allarity Therapeutics获机构升目标价至9.25美元，维持"买入"评级
今日重点评级关注：Ascendiant Capital：维持Allarity Therapeutics"买入"评级，目标价从9美元升至9.25美元；JMP证券：维持Crinetics Pharmaceuticals"跑赢大市"评级，目标价从86美元升至143美元
09-29 09:15
美股周涨跌榜 | 股价狂飙近300%！uniQure在研创新药获突破进展；特朗普政府寻求入股Lithium
股价周内狂飙近300%！uniQure在研创新药获重大进展；特朗普政府"盯上"锂矿巨头股权，Lithium Americas周内大涨95%>>
09-28 10:10
FDA Approves Crinetics Pharma's First Daily Pill For Rare Growth Disorder
On Thursday, the U.S.
09-27 01:07
Crinetics飙升26.6%，其肢端肥大症治疗药物获FDA批准
制药企业Crinetics Pharmaceuticals(CRNX)早盘飙升26.6%，获得美国FDA对肢端肥大症治疗药物Palsonify的批准。批准基于成...
09-26 22:57
Assessing Crinetics Pharmaceuticals: Insights From 4 Financial Analysts
Throughout the last three months, 4 analysts have evaluated Crinetics Pharmaceuticals (NASDAQ: CRNX), offering a diverse set of opinions from bullish to bearish. Summarizing their recent assessments, the table below illustrates the evolving sentiments in the past 30 days and compares them to the preceding months.
09-26 22:00
